$6.24
3.85% day before yesterday
Nasdaq, Dec 27, 09:48 pm CET
ISIN
US25056L1035
Symbol
DSGN

Design Therapeutics Inc Stock price

$6.25
+0.28 4.69% 1M
+2.90 86.57% 6M
+3.60 135.85% YTD
+3.55 131.48% 1Y
-12.01 65.77% 3Y
-13.75 68.75% 5Y
-13.75 68.75% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.24 3.70%
ISIN
US25056L1035
Symbol
DSGN
Sector
Industry

Key metrics

Market capitalization $353.88m
Enterprise Value $102.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.40
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.81m
Free Cash Flow (TTM) Free Cash Flow $-46.41m
Cash position $254.07m
EPS (TTM) EPS $-0.85
Short interest 10.61%
Show more

Is Design Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Design Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

Buy
33%
Hold
67%

Financial data from Design Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.59 0.59
7% 7%
-
-0.59 -0.59
7% 7%
-
- Selling and Administrative Expenses 17 17
21% 21%
-
- Research and Development Expense 43 43
29% 29%
-
-60 -60
26% 26%
-
- Depreciation and Amortization 0.59 0.59
7% 7%
-
EBIT (Operating Income) EBIT -61 -61
26% 26%
-
Net Profit -48 -48
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Design Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Design Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Well-Capitalized with Cash and Securit...
Neutral
GlobeNewsWire
5 months ago
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials

Company Profile

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.

Head office United States
CEO Pratik Shah
Employees 124
Founded 2017
Website www.designtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today